Cover Image


Small Molecule Cancer Drug Clinical Pipeline Insight

出版商 PNS Pharma 商品編碼 323224
出版日期 內容資訊 英文 1650 Pages
商品交期: 最快1-2個工作天內
Back to Top
小分子癌症治療藥的臨床實驗平台分析 Small Molecule Cancer Drug Clinical Pipeline Insight
出版日期: 2015年01月22日 內容資訊: 英文 1650 Pages



第1章 所謂小分子癌症治療藥

第2章 癌症治療的小分子藥所扮演的角色

第3章 小分子癌症治療藥的機制

第4章 小分子癌症治療藥的市場概要

  • 目前市場方案
  • 臨床實驗平台概要

第5章 小分子癌症治療藥的市場動態

  • 推動市場要素
  • 臨床、商業化的課題

第6章 小分子癌症治療藥市場未來發展預測

第7章 小分子癌症治療藥的臨床實驗平台:各企業、適應、階段

  • 階段不明
  • 研究
  • 前臨床
  • 臨床
  • 階段0
  • 階段I
  • 階段I/II
  • 階段II
  • 階段II/III
  • 階段III
  • 預註冊
  • 登記完畢

第8章 已上市小分子癌症治療藥臨床分析

第9章 競爭情形

  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Cadila Pharmaceutical
  • Eli Lily
  • GalaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sun Pharmaceuticals



Oncologists are continuously looking for better therapeutic options to effectively cure and prevent different types of malignancies. Conventionally, surgery and radiation were widely used for cancer treatment but they have modest benefits. Presently, global market consists of several options for cancer treatment which belongs to various classes of molecules. Their utilization in therapeutic regime depends on the patient's medical condition, pharmacological and financial benefits offered by them during treatment. Out of these classes of therapeutic molecules, small molecules have been found to have substantial impact on cancer treatment due to which they are widely accepted by oncologists and patients.

Small molecules are widely used for cancer treatment because they can easily infiltrate into the tumorous cells and prevent its proliferation. Chemotherapeutic drugs are also small molecules, generally used in cancer treatment for several decades. They are still used as first line cancer therapeutics and they have highly developed cancer market. Chemotherapeutics have helped in decreasing the mortality rates but their severe side effects cause high morbidity rates. This fact made the researchers to search for other small molecules which can provide better pharmacological effects with minimized side effects in cancer patients. As a result, after several decades of research newer small molecules belonging to different classes have been formulated for cancer treatment.

High versatility is another benefit offered by small molecule due to which they can be used for the treating different types of cancers. Research in this field is progressing and several molecules are under investigation for their pharmacological efficacy. Conventional therapies in cancer of sensitive tissue may have life threatening effects instead of therapeutic benefit. For instance, a newly discovered molecule called TIC10 has been found as a potential treatment against brain tumour. It is under development at laboratory phase and someday it may enter in clinical trials in coming years. Many other small molecules are under development for the treatment of Non-Small Cell Lung Cancer (NSCLC), Colon cancer, Breast and other cancers.

Development of small molecule cancer drug generally involves target identification and pharmacological efficacy provided during clinical trials. Different types of cancer have different physiological characteristics due to which effective treatment requires the small molecule showing preferential selectiveness towards a particular cell group. Technological limitations are one of the biggest hindrances in the speedy development of small molecules for cancer treatment but this is expected to be overcome with time due to increased investments in research and development segment. New small cancer drugs based on novel technology are expected to enter in global market in coming years.

“Small Molecule Cancer Drug Clinical Pipeline Insight” Report Findings:

  • Role of Small Molecule Drug in Cancer Treatment
  • Mechanism of Small Molecule Cancer Drug
  • Small Molecule Cancer Drugs Market Dynamics
  • Small Molecule Cancer Drug Clinical Pipeline By Company, Indication & Phase
  • Small Molecule Cancer Drug Clinical Pipeline: 1108 Drugs
  • Marketed Small Molecule Cancer Drugs: 128
  • Majority of Drugs are in Preclinical Phase: 437 Drugs

Table of Contents

1. Introduction to Small Molecule Cancer Drug

2. Role of Small Molecule Drug in Cancer Treatment

3. Mechanism of Small Molecule Cancer Drug

4. Small Molecule Cancer Drugs Market Overview

  • 4.1. Current Market Scenario
  • 4.2. Clinical Pipeline Overview

5. Small Molecule Cancer Drugs Market Dynamics

  • 5.1. Market Drivers
  • 5.2. Clinical & Commercialization Challenges

6. Small Molecule Cancer Drug Market Future Prospects

7. Small Molecule Cancer Drug Clinical Pipeline By Company, Indication & Phase

  • 7.1. Unknown
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Clinical
  • 7.5. Phase-0
  • 7.6. Phase-I
  • 7.7. Phase-I/II
  • 7.8. Phase-II
  • 7.9. Phase-II/III
  • 7.10. Phase-III
  • 7.11. Preregistration
  • 7.12. Registered

8. Marketed Small Molecule Cancer Drugs Clinical Insight

9. Competitive Landscape

  • 9.1. AstraZeneca
  • 9.2. Bayer
  • 9.3. Boehringer Ingelheim
  • 9.4. Cadila Pharmaceutical
  • 9.5. Eli Lily
  • 9.6. GalaxoSmithKline
  • 9.7. Johnson & Johnson
  • 9.8. Merck
  • 9.9. Novartis
  • 9.10. Pfizer
  • 9.11. Roche
  • 9.12. Sun Pharmaceuticals

List of Figures:

  • Figure 1-1: Characteristics of Small Molecule Drugs
  • Figure 2-1: Benefits of Small Molecule Drugs in Cancer Treatment
  • Figure 3-1: Mechanism of Chemotherapeutic Agents
  • Figure 3-2: Mechanism of Doxorubicin Chemotherapeutic Agent
  • Figure 3-3: Mechanism of Tamoxifen Estrogen Antagonist
  • Figure 3-4: Mechanism of Abiraterone
  • Figure 3-5: Mechanism of Afatinib Kinase Inhibitor
  • Figure 3-6: Mechanism of Multiple Target Sorafenib
  • Figure 3-7: Mechanism of Imatinib Mesylate
  • Figure 3-8: Mechanism of Bortezomib Proteosome Inhibitor
  • Figure 3-9: Mechanism of Vintafolide Small Molecule Drug Conjugate
  • Figure 4-1: Small Molecule Cancer Drug Clinical Pipeline by Phase (%), 2015
  • Figure 4-2: Small Molecule Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2015
  • Figure 5-1: Drivers for Small Molecule Cancer Drugs
Back to Top